With this trial now successfully completed, a further commercial arrangement is under negotiation with parties to run the final required trial, with possibilities still available for inward investment in exchange for regional commercialisation rights, equity positions in ValiSeek, or options for future commercial rights.
As complete oral formulation, VAL401 will provide a potential cancer treatment with a good safety profile, with a clear route to market supported scientifically by the extensive history of the drug’s use, yet protected commercially by the detail of the reformulation.
For asking a dumb question but £454,000 given at 1p each should only add another 45 million shares. Then why are we talking about doubling of share in issue???
I was just going through the profiles of everyone who works at VAL. They all are very experienced people in their respective field.
Although, we all have our doubts about the success of this company but if you read about each individual and their achievements, then that kind of reassures you that we are in good hands. HOPE FOR A GREAT END :)
Mark Treharne 3rd degree connection3rd Business Development Manager at RIVERFORT GLOBAL CAPITAL London, United Kingdom Current: Corporate Development Manager at Valirx plc